Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, November 2001, p. 1131-1135, Vol. 8, No. 6
1071-412X/01/$04.00+0 DOI: 10.1128/CDLI.8.6.1131-1135.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Calcein-Acetyoxymethyl Cytotoxicity Assay:
Standardization of a Method Allowing Additional Analyses on
Recovered Effector Cells and Supernatants
Simona
Neri,1
Erminia
Mariani,1,2,*
Alessandra
Meneghetti,2
Luca
Cattini,2 and
Andrea
Facchini1,2
Dipartimento di Medicina Interna e
Gastroenterologia, University of Bologna,1 and
Laboratorio di Immunologia e Genetica, Istituto di Ricerca
Codivilla-Putti IOR,2 Bologna, Italy
Received 2 April 2001/Returned for modification 25 June
2001/Accepted 17 August 2001
 |
ABSTRACT |
Cytotoxicity assays provide an in vitro evaluation of the lytic
activity of NK and T cells against tumors or transformed cells. However, none of these methods allow the recovery of cells or supernatants after the assay. We standardized a microcytotoxicity test
using calcein-acetoxymethyl (calcein-AM) dye that requires very small
quantities of cells while maintaining the same sensitivity as the
traditional 51Cr assay. The assay is applicable to resting
as well as activated human effector cells and uses different targets
such as human cell lines that are adherent or growing in suspension and
resistant or sensitive. The most important feature of the method is the possibility of recovering cells and supernatants for additional analyses such as phenotyping and evaluation of soluble factors.
 |
INTRODUCTION |
Cytotoxicity assays provide
an in vitro evaluation of the lytic activity of natural killer (NK) and
T cells against tumors or transformed target cells (3, 16,
25). In in vitro experimental conditions, lytic activity is
evaluated using isotopes or dyes either released from dead cells or
retained by living ones. The 51chromium
(51Cr) release assay is the most widely used
method although it has several significant drawbacks. The major
disadvantage results from the use of a radioactive compound, with the
related problems of handling and disposal due to the short half-life of
the isotope.
To overcome these problems, several nonradioactive methods have been
developed, but none have yet found a broad acceptance, probably due to
a lack of comparability of their results with the results obtained
using the 51Cr release assay, which still remains
the most popular. Some alternative methods consist of measuring
endogenous or transfected reporter enzymes released in the supernatant
by dead targets (1, 11, 19, 24). Other assays using
nonradioactive compounds (dimethylthiazol-diphenyl bromide tetrazolium
bromide, methylumbelliferyl heptanoate, Alamar blue) evaluate the
variations in metabolic activity, which is directly proportional to the
number of viable cells (6, 18). Alternative methods using
fluorochromes (e.g., europium, D275, rhodamine-123, carboxyfluorescein
diacetate, bis-carboxyethyl-carboxyfluorescein) (7, 9, 12, 14,
23, 26, 28) measure the amount of dye released from or remaining
in prelabeled target cells (2, 8, 13). The major drawbacks
for these methods appear to be the high spontaneous release of the
fluorescent dye, the slow specific release of the fluorescein dye, and
the low intensity of the fluorescence signal, all of which decrease the
overall sensitivity of the test.
Among fluorescent dyes, the use of calcein-acetoxymethyl (calcein-AM)
in cytotoxicity assays has already been described (13, 21,
22). This dye has good retention in targets and low pH sensitivity, and there is no stain transfer among cells
(21). Acetoxymethyl ester of calcein is a lipid-soluble
diester fluorogenic esterase substrate that passively crosses the cell
membrane and that is frequently used to stain viable cells. Inside the
cells it is converted by intracellular esterases into a polar
lipid-insoluble fluorescent product (calcein) that is retained by cells
with intact membranes but that is released by damaged ones (similarly
to 51Cr), producing an intense green signal.
Release of calcein in the supernatants recovered from cytotoxicity
assays can be measured rapidly and with a high level of sensitivity by
a fluorimeter. Alternatively, lytic activity could be determined by
measuring the fluorescence retained in living cells after quenching the fluorescence released by dead targets (22, 27).
Frequently, cytotoxicity tests are limited by the number of available
effector cells, as for poorly represented cellular subpopulations (such
as NK subsets and sorted or cloned lymphocytes) or by small amounts of
blood (e.g., from children and elderly people). In these situations,
the ability to use a low number of effector cells and the ability to
recover cells after the cytolytic activity test would greatly
facilitate the performance of the assays.
Our objectives were (i) to test the possibility of recovering cells and
supernatants after the calcein-AM cytotoxicity assay for additional
analyses, such as membrane phenotyping tests and enzyme-linked
immunosorbent assays (ELISA) in order to further optimize the use of
the cell samples (this recovery is not possible when radioactive
labeling is used), (ii) to standardize the calcein-AM cytotoxicity
assay under the same conditions used in the 51Cr
microassay previously described (16) and to demonstrate
that the calcein-AM assay gives comparable results, and (iii) to
evaluate the reliability of the method for the determination of NK
lytic activity against adherent sensitive or resistant osteosarcoma tumor cell lines.
 |
MATERIALS AND METHODS |
Target tumor cells.
Four different cell lines, all obtained
from the American Type Culture Collection (Manassas, Va.), were used as
targets: K562, Molt-4, HOS, and Saos-2. K562 is an NK-susceptible
erythroleukemia cell line, and Molt-4 is a relatively NK-resistant
T-lymphoblastoid cell line. They grow in suspension in complete medium:
RPMI 1640 (Sigma, St. Louis, Mo.) supplemented with 10%
heat-inactivated fetal calf serum (Biological Industries, Kibbutz Beit
Hacmek, Israel), 4 mM glutamine (Sigma), and 200 µg of
gentamicin (Biological Industries)/ml. Cells were kept at log growth
phase before use in the experiments. HOS and Saos-2 are human
osteoblastic-like tumor cell lines that grow as adherent cells in
complete medium. Before use in the experiments, cells in the
logarithmic growth phase were detached from monolayers with
trypsin-EDTA (Sigma), washed twice, and used as targets.
2.2. Effector cells.
Total lymphocytes (peripheral blood
mononuclear cells [PBMC]) were separated from the peripheral blood of
11 healthy human volunteers by density gradient centrifugation,
resuspended at the optimal concentration (2.5 × 106/ml) in complete medium, and used as effector cells.
51Chromium release assay.
NK cell lytic activity
was tested against K562 using a standard chromium release assay
(16). The test was performed in V bottom 96-well
microtiter plates (Nunc, Roskilde, Denmark). Cells at various
effector-to-target (E:T) cell ratios (from 50:1 to 0.5:1) were
seeded in triplicate together with 51Cr-labeled
target cells, as previously described (15). After 4 h
at 37°C in 5% CO2, 1/2 volume of each
supernatant (75 µl) was harvested and counted in a Topcount
microplate scintillation gamma counter (Packard, Meriden, Conn.). Data
were acquired in counts per minute. Specific lysis was calculated
according to the formula [(test release
spontaneous
release)/(maximum release
spontaneous release)] × 100 (5, 20). Spontaneous release represents
51Cr release from target cells in medium alone,
and maximum release is the 51Cr release from
target cells lysed in medium plus 2% Triton X-100, each measured in at
least six replicate wells.
Calcein-AM release assay (macro- and microassay).
Calcein-AM
was purchased from Molecular Probes (Eugene, Oreg.) as a 1-mg/ml
solution in dry dimethyl sulfoxide. Target cells were resuspended in
complete medium at a final concentration of 106/ml and incubated with 15 µM calcein-AM for
30 min at 37°C with occasional shaking. After two washes in complete
medium cells were adjusted to 105/ml (macroassay)
or to 104/ml (microassay). The test was performed
in the same way as the 51Cr assay in V bottom
96-well microtiter plates (Nunc), with E:T ratios ranging from 50:1 to
0.5:1, in triplicate, and with at least six replicate wells for
spontaneous (only target cells in complete medium) and maximum release
(only target cells in medium plus 2% Triton X-100). Various numbers of
mononuclear effector cells and labeled tumor target cells were seeded
as follows. For the macroassay (standard) each well contained from
2.5 × 105 to 2.5 × 103 lymphocytes in 100 µl of complete medium
and 5 × 103 target cells/50 µl of
complete medium; for the microassay a 10-fold-lower dilution of both
effector and target cells was used. After incubation at 37°C in 5%
CO2 for 4 h, 75 µl of each supernatant was
harvested and transferred into new plates. Samples were measured using
a Spectramax Gemini dual-scanning microplate spectrofluorimeter (Molecular Devices, Sunnyvale, Calif.) (excitation filter: 485 ± 9 nm; band-pass filter: 530 ± 9 nm). Data were expressed as arbitrary fluorescent units (AFU). Percent lysis was calculated with
the same formula used for the 51Cr assay.
Cytokine treatment.
To evaluate the possibility of detecting
an increase in the lytic activity using the calcein-AM assay,
lymphocytes were previously incubated with 100 U of recombinant human
interleukin-2 (rhIL-2; Glaxo, Geneva, Switzerland)/ml or 10 ng
of rhIL-12 (R&D Systems Europe Ltd., Abingdon, United Kingdom)/ml for
18 h. Untreated lymphocytes were used as controls. After
incubation, lymphocytes were washed in complete medium and used in the
standard calcein-AM cytotoxicity assay.
Analysis of cell pellets and supernatants recovered after the
cytotoxicity assay.
PBMC used for immunophenotyping were either
fresh or recovered after the cytotoxicity assay. Samples were washed
three times with phosphate-buffered saline-2% fetal calf serum-0.1%
sodium azide, adjusted to approximately 105 cells
in 100 µl of the same buffer, and labeled with phycoerythrin (PE)-conjugated monoclonal antibody (MAb) CD-8 or CD-56 (Becton Dickinson) and Cy5-conjugated MAb CD-16 (Caltag Laboratories, Burlingame, Calif.). Incubations with MAbs were performed for 30 min at
4°C. Negative-control cells were incubated with an immunoglobulin isotype control. Analysis was performed by flow cytometry (4, 16).
Cell-free supernatants from 10 samples were collected before and
after the calcein-AM cytotoxicity test (E:T ratio, 50:1). Four of these
samples were also tested after 18 h of incubation with 100 U of
rhIL-2/ml. RANTES levels were measured by a sandwich quantitative
immunoassay with anti-human RANTES matched antibody pairs (Pharmingen).
The standard curve range was from 15.6 to 2,000 pg/ml.
Statistical analysis.
Experimental data are expressed as
means ± standard errors of the means (SEM). Statistical
significance was evaluated using Student's t test for
paired data, and regression analysis was performed to compare results.
The Statistics for Windows package was used to carry out statistical analyses.
 |
RESULTS |
Comparison of cytotoxicity evaluated by 51Cr and
calcein-AM release assays.
To evaluate the efficacy of the
calcein-AM cytotoxicity assay, tests were performed in parallel to the
51Cr standard procedure using the same target
(K562) and effector cells, the only difference being the labeling of
the targets. Maximum- and spontaneous-release values corresponded,
respectively, to 17,769 ± 3,991 and 1,506 ± 318 cpm
for the 51Cr assay and 5,935 ± 405 and
2,186 ± 171 AFU for the calcein-AM assay. The mean spontaneous
releases from K562 cells were about 10 and about 34% of the maximum
for 51Cr and calcein-AM assays, respectively . Target cell viability was not affected by calcein-AM staining, as
assessed by the eosin exclusion test (data not shown). To further
confirm that the higher spontaneous release with calcein-AM than with
51Cr was not due to a poor dye-dependent target
cell viability, a double labeling of K562 cells, first with calcein-AM
and subsequently with 51Cr, was performed.
Spontaneous release of 51Cr in these cells was
similar to spontaneous release in the same cells labeled only with
51Cr (4.5 versus 6% of
51Cr release; mean of three experiments).
As shown in Fig.
1a, the mean curves from
all 11 analyzed samples obtained with both methods overlapped.
Regression analysis
performed by plotting mean percentages of
51Cr release against the corresponding mean
percentages of calcein-AM
release (Fig.
1b) indicated a close positive
correlation between
the two methods (
P < 0.001).

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 1.
Comparison of the 51Cr and the calcein-AM
cytotoxicity release assays of K562 target cells. (a) Results are
expressed as mean percentages of release ± SEM for 11 experiments
run in parallel. (b) Regression analysis. Each point represents the
mean values of paired observations for all the E:T ratios tested. The
fitted line is y = 3.6322 + 0.94794x
(correlation coefficient, r = 0.994;
P < 0.001). Dotted lines, 95% confidence
interval.
|
|
Comparison between calcein-AM macro- and microassay.
The
correlation between the calcein-AM release macro- and microassays was
evaluated in comparative experiments. For the microassays we utilized a
10-fold-lower concentration of targets and effectors than in the
macroassays. The curves obtained using 5,000 or 500 K562 target cells
overlapped (Fig. 2a). Mean maximum
release obtained from 500 K562 cells was 4,994 ± 568 AFU,
with a spontaneous release that never exceeded 40% of the maximum.
Regression analysis performed by plotting mean percentages of calcein
release obtained with macro- and microassays indicated a very close
positive correlation (P < 0.001) (Fig. 2b). A
significant positive correlation was also observed by plotting mean
percentages of calcein and chromium released with a microassay
(r = 0.997, P < 0.005) (not shown).

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 2.
Comparison of cell-mediated cytotoxicity detected using
the calcein-AM macro- or microassay of K562 target cells. (a) Results
are expressed as mean percentages of release ± SEM for 11 experiments run in parallel. (b) Regression analysis. The fitted
line is y = 1.9009 + 0.89479x
(r = 0.993; P < 0.001). Dotted
lines, 95% confidence interval.
|
|
Evaluation of NK stimulation by calcein-AM assay.
We also
tested the ability of the calcein-AM method to detect the increase of
lytic activity induced by interleukin-2 (IL-2) or IL-12 treatment of
PBMC against K562 cells. An evident increase in calcein release occurs
after 18 h of IL-2 incubation for all E:T ratios tested
(P < 0.05) (Fig. 3a).
Incubation of PBMC with IL-12 similarly enhanced lytic activity (Fig.
3c) (P < 0.05) for all the E:T ratios except at 3:1.
Regression analysis performed by plotting mean percentages of calcein
release versus chromium release obtained following cytokine incubation
showed a very close positive correlation for both IL-2 (Fig. 3b) and
IL-12 (Fig. 3d) stimulations (P < 0.001, at least).

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 3.
Increase in lytic activity after cytokine treatment,
detected by calcein-AM release assay. Shown is the lytic activity of
four samples of PBMC, which were either resting (ns) or treated for
18 h with 100 U of IL-2/ml (a) or with 10 ng of IL-12/ml (c),
against K562 cells. Results are mean percentages of release ± SEM
(P < 0.05 for all the E:T ratios, except for the
3:1 ratio (c). (b and d) Regression analysis. Each point represents the
mean value of paired observations for all the E:T ratios tested. The
fitted line for IL-2-stimulated lymphocytes (b) is
y = 6.758 + 1.0778x (correlation
coefficient, r = 0.999; P < 0.001). The fitted line for IL-12-stimulated lymphocytes (d) is
y = 14.53 + 1.1770x (correlation
coefficient, r = 0.997; P < 0.005). Dotted lines, 95% confidence interval.
|
|
Calcein-AM assay using sensitive and resistant cell lines.
The
calcein-AM method is also efficient using cell lines relatively
resistant to NK lysis, such as Molt-4, as targets. Results indicated a
significant difference in percent lysis at all E:T ratios compared to
K562 targets, in agreement with the traditional 51Cr release assay (Fig.
4a).

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 4.
Cytolytic activity against sensitive and resistant human
cell lines measured by calcein-AM assay. (a) Human cell lines growing
in suspension. Shown are means ± SEM of four experiments with
PBMC tested against K562 and Molt-4 cells. Dashed line, results
obtained by 51Cr assay using Molt-4 cells. (b) Adherent
human osteosarcoma cell lines. Shown are means ± SEM of four
experiments with PBMC tested against HOS and Saos-2 cells. Dashed
lines, results obtained by 51Cr assay using HOS (closed
symbols) and Saos-2 (open symbols).
|
|
The calcein-AM assay was also able to measure cytotoxicity against two
adherent osteosarcoma cell lines, HOS and Saos-2. After
detachment, a
macroassay was performed. Maximum- and spontaneous-release
values were,
respectively, 5,854 ± 1,/0 and 1,849 ± 277 AFU for
HOS
cells and 5,292 ± 345 and 1,485 ± 68 AFU for Saos-2.
Results
indicated that HOS cells are more sensitive to NK lysis than
Saos-2
cells (Fig.
4b), with a statistically significant difference
between
release values from 50:1 to 0.5:1 ratios (
t test for
paired data;
P < 0.05), similar to results for the
51Cr release
assay.
Recovery of cell pellets and supernatants after the calcein-AM
assay.
The use of a nonradioactive compound makes it possible to
recover cells after the cytotoxicity assay for additional analyses. Lymphocytes recovered from cytotoxicity plates together with target cells were directly labeled with MAbs that recognize surface molecules on cytolytic cells: PE-conjugated anti-CD8 and anti-CD16 and
Cy5-conjugated anti-CD56. The percentages of positive
lymphocytes recovered after cytotoxicity assays were similar to
those obtained with the same cells before performing cytotoxicity
assays, as were the fluorescence intensities (Fig.
5). K562 cells were electronically
excluded from the analysis on the basis of their different size.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 5.
Fluorescence histograms obtained by
fluorescence-activated cell sorter analysis of membrane phenotype after
a calcein-AM cytotoxicity assay. PBMC effectors that were fresh (a to
c) or recovered after the assay (a' to c') were labeled with CD8-PE and
CD16-Cy5 or CD56-PE. Percentages of positive lymphocytes and mean
fluorescence channels (MFC) are indicated. One representative
observation of 10 performed is shown.
|
|
Cell-free supernatants recovered after the cytotoxicity assay could
also be used in an ELISA. Supernatants before and after
the
cytotoxicity assay (E:T ratio, 50:1) were collected from 10
samples and
used to evaluate the production of the chemokine RANTES,
which seems to
be unmodulated during cytotoxicity assays (personal
preliminary
observations). RANTES levels in unstimulated samples
before and after
calcein-AM test were, respectively, 607 ± 81
and 645 ± 73 pg/ml. After treatment of four of these samples with
IL-2 for 18 h, the RANTES level in supernatants recovered after
the cytotoxicity
assay was significantly increased (850.3 ± 183
pg/ml) with
respect to that for the corresponding unstimulated
samples (625 ± 169 pg/ml;
P < 0.05), but it was similar to the
amount
of chemokine found in supernatants of IL-2-stimulated lymphocytes
for
which the cytotoxicity assay was not performed (927 ± 145
pg/ml).
 |
DISCUSSION |
NK cells play an important role in the cellular recognition and
killing of virus-infected and tumor cells. The evaluation of lytic
activity is therefore of great importance in monitoring the functional
capability of these cells. Traditionally, cytotoxicity is measured by
the 51Cr release assay (3), which
has several disadvantages, including the use of a radioactive label and
the time required to process samples. Several alternative approaches
using fluorescent dyes have been proposed (2, 7-9, 12-14,
21-23, 26-28).
In the present study, we describe a modification of an easy and fast
method for measuring lytic activity using a fluorescent nonradioactive
compound (calcein-AM). This dye has good retention in living cells,
bright fluorescence, and reduced spontaneous leakage compared to other
fluorescent molecules such as, bis-carboxyethyl-carboxyfluorescein and
carboxyfluorescein diacetate (13, 27). Labeling target cells with calcein-AM has been shown to have no effect on the formation
of effector-target conjugates (4), and the intense green
fluorescent stain is stable for at least 4 h (13).
Calcein-AM cytotoxicity assays based on the evaluation of dye released
in the supernatant used a relatively high number of target cells (15 × 103) (13); the number of
targets used for the evaluation of dye retained by living cells (3 × 103) was also relatively high
(22), except in a study in which the test was performed
using Terasaki trays and 5 × 102 targets in
5 µl of medium (27). The method that we standardized requires very small quantities of cells to evaluate the dye released in
the supernatant (500) and maintains the same experimental procedures and working volumes as in the 51Cr assay. We
found a strict correlation between results, with no significant
differences in the experimental release values, making it possible to
compare data obtained using the two different techniques. Furthermore,
by reducing in the number of cytolytic effector and target cells
10-fold, without reducing working volumes, we obtained results very
similar to those of the standard calcein-AM test. The microassay is
therefore as reliable as the standard one, and this is of great
importance when small amounts of blood are available, as in studies on
elderly people or children. Fluorescent calcein released from lysed
cells can be easily and readily measured in the recovered supernatants
using a standard automated plate-reading fluorimeter. The entire
procedure is analogous to the chromium release assay but requires less
time to perform. In fact, while the standard 51Cr
assay requires 1 h to label target cells, calcein-AM labeling is
performed in 30 min. In addition, the former method has slow processing
times when large numbers of samples have to be counted (1 min per
well), while with the calcein-AM assay and the Spectramax fluorimeter
the detection time can be standardized to less than 1 s per well.
We found that spontaneous release of calcein is significantly higher
than that of 51Cr, particularly in the
microassay, in accordance with previous findings
(13). This higher spontaneous release does not depend on
poor target cell viability caused by calcein-AM, as demonstrated by
performing a double labeling of K562 cells with calcein-AM and
subsequently with 51Cr. The technique shows
sensitivities similar to those for 51Cr labeling
while maintaining specificity. In effect, the difference between
results never reached statistical significance, both assays revealing
the same functional correlation. The slightly higher sensitivity of the
calcein-AM assay could allow a reduction of the incubation time to less
than 4 h, probably even reducing the spontaneous release rate.
However, spontaneous release did not seem to be influenced by the dye
concentration (13).
IL-2- and IL-12-activated total PBMC lyse the NK-susceptible K562 cells
with more efficiency (10, 15), and this effect may also
have been revealed by the calcein-AM assay, which is therefore
applicable to studies of cytotoxicity with resting as well as activated
human effector cells.
We also tested the calcein-AM assay in cytotoxicity tests against the
relatively resistant Molt-4 cells, obtaining results comparable to
those of the standard chromium technique. To our knowledge, there were
no available data regarding the use of the calcein-AM assay to test
lytic activity against adherent human osteosarcoma cell lines. Using
cell lines HOS and Saos-2 as targets we observed that both lines
retained calcein, maintained viability after staining, and displayed a
spontaneous release similar to that of targets not treated with
detaching enzymes (K562 and Molt-4). HOS cells were found to be more
susceptible to lysis than Saos-2, in accordance with previous
observations obtained with the 51Cr assay
(17). The amount of lysis and the degree of the
susceptibility of the two cell lines obtained with the calcein-AM assay
were equivalent to those obtained with
51Cr.
A very important feature of the method is that cells can be recovered
and the supernatants can be used again for additional biological
analyses. This may provide numerous advantages in terms of quantities
of material required and also may enable the characteristics of the
cells or their soluble products to be studied after their lytic
potential has been determined. We demonstrated that recovered cells
could be labeled with MAbs. Labeling with PE or Cy5 MAbs that recognize
molecules of the lymphocyte cell surface gave very similar results
before and after determination of cytotoxicity with calcein.
Fluorescein isothiocyanate (FITC)-conjugated antibodies were not used
to avoid possible interference with the green fluorescence of calcein.
In effect, even if K562 calcein-labeled targets could be electronically
excluded from the analysis because of their different size, there is a
weak interference of calcein present in the medium with effector cells,
giving rise to a little shifting of the lymphocyte green fluorescence
or a randomly distributed low autofluorescence signal (<10%) (data
not shown). FITC-conjugated antibodies could therefore be used only to
label surface molecules with high density or expressed in
well-represented subpopulations.
We also demonstrated the possibility of using supernatants to evaluate
soluble factors produced during the cytotoxicity assay. We observed
that the presence of calcein was compatible with the development of an
ELISA either with fresh cells or with interleukin-activated lymphocytes, for example, for the detection of the RANTES chemokine, chosen because it is not modulated during effector-target cell interactions.
In conclusion, the calcein-AM-based method seems to be a very good
candidate for a substitute for the standard 51Cr
assay because it is sensitive, easy, safe, and useful for different types of targets and because cells and supernatants can be recovered to
perform additional analyses, especially when limited amounts of blood
are available.
 |
ACKNOWLEDGMENTS |
This work was partially supported by grants from MURST (60%
fund), Ricerca Corrente IOR, FP Health Ministry from Italy and ImAginE
framework from the EU (QLK6-CT-1999-02031).
We thank Keith Smith for revising the English manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Laboratorio di
Immunologia e Genetica, Istituto di Ricerca Codivilla-Putti I.O.R., Via
di Barbiano 1/10, 40136 Bologna, Italy. Phone: 39051-6366803. Fax:
39051-6366807. E-mail: marianie{at}alma.unibo.it.
 |
REFERENCES |
| 1.
|
Bachy, M.,
A. Bonnin-Rivalland,
V. Tilliet, and E. Trannoy.
1999.
Beta galactosidase release as an alternative to chromium release in cytotoxic T-cell assays.
J. Immunol. Methods
230:37-46[Medline].
|
| 2.
|
Blomberg, K., and A. C. Ulfstedt.
1993.
Fluorescent europium chelates as target cell markers in the assessment of natural killer cell cytotoxicity.
J. Immunol. Methods
160:27-34[CrossRef][Medline].
|
| 3.
|
Brunner, K. T.,
J. Mauel,
J. C. Cerottini, and B. Chapuis.
1968.
Quantitative assay of the lytic action of immune lymphoid cells on 51Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and drugs.
Immunology
14:181-196[Medline].
|
| 4.
|
Callewaert, D. M.,
G. Radcliff,
R. Waite,
J. LeFevre, and M. D. Poulik.
1991.
Characterization of effector-target conjugates for cloned human natural killer and human lymphokine activated killer cells by flow cytometry.
Cytometry
12:666-676[CrossRef][Medline].
|
| 5.
|
Facchini, A.,
E. Mariani,
A. R. Mariani,
S. Papa,
M. Vitale, and F. A. Manzoli.
1987.
Increased number of circulating Leu 11+ (CD16) large granular lymphocytes and decreased NK activity during human ageing.
Clin. Exp. Immunol.
68:340-347[Medline].
|
| 6.
|
Hussain, R. F.,
A. M. E. Nouri, and R. T. D. Oliver.
1993.
A new approach for measurement of cytotoxicity using colorimetric assay.
J. Immunol. Methods
160:89-96[CrossRef][Medline].
|
| 7.
|
Iwao, M.,
C. Ochi,
I. Kurane, and S. Muraoka.
1998.
A non-radioisotopic human natural killer cell assay using rhodamine-123 fluorescent dye as labelling probe.
Immunol. Investig.
27:31-45[Medline].
|
| 8.
|
Johann, S.,
G. Blumel,
M. Lipp, and R. Forster.
1995.
A versatile flow cytometry-based assay for the determination of short- and long-term natural killer cell activity.
J. Immunol. Methods
185:209-216[CrossRef][Medline].
|
| 9.
|
Kolber, M. A.,
R. R. Quinones,
R. E. Gress, and P. A. Henkart.
1988.
Measurement of cytotoxicity by target cell release and retention of the fluorescent dye bis-carboxyethyl-carboxyfluorescein (BCECF).
J. Immunol. Methods
108:255-264[CrossRef][Medline].
|
| 10.
|
Konjevic, G.,
B. Schlesinger,
L. Cheng,
K. J. Olsen,
E. R. Podack, and I. Spuzic.
1995.
Analysis of perforin expression in human peripheral blood lymphocytes, CD56+ natural killer cell subsets and its induction by interleukin-2.
Immunol. Investig.
24:499-507[Medline].
|
| 11.
|
Korzeniewski, C., and D. M. Callewaert.
1983.
An enzyme-release assay for natural cytotoxicity.
J. Immunol. Methods
64:313-320[CrossRef][Medline].
|
| 12.
|
Kroesen, B. J.,
G. Mesander,
J. G. ter Haar,
T. H. The, and L. de Leij.
1992.
Direct visualisation and quantification of cellular cytotoxicity using two colour fluorescence.
J. Immunol. Methods
156:47-54[CrossRef][Medline].
|
| 13.
|
Lichtenfels, R.,
W. E. Biddison,
H. Schulz,
A. B. Vogt, and R. Martin.
1994.
CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity.
J. Immunol. Methods
172:227-239[CrossRef][Medline].
|
| 14.
|
Lövgren, J., and K. Blomberg.
1994.
Simultaneous measurement of NK cell cytotoxicity against two target cell lines labelled with fluorescent lanthanide chelates.
J. Immunol. Methods
173:119-125[Medline].
|
| 15.
|
Mariani, E.,
A. Meneghetti,
A. Tarozzi,
L. Cattini, and A. Facchini.
2000.
IL-12 induces efficient lysis of NK sensitive and NK resistant human osteosarcoma cells. The synergistic effect of IL-2.
Scand. J. Immunol.
51:618-625[Medline].
|
| 16.
|
Mariani, E.,
M. C. G. Monaco,
S. Sgobbi,
J. F. de Zwart,
A. R. Mariani, and A. Facchini.
1994.
Standardization of a micro-cytotoxicity assay for human natural killer cell lytic activity.
J. Immunol. Methods
172:173-178[Medline].
|
| 17.
|
Mariani, E.,
A. Tarozzi,
A. Meneghetti,
L. Cattini, and A. Facchini.
1997.
Human osteosarcoma cell susceptibility to natural killer cell lysis depends on CD54 and increases after TNF incubation.
FEBS Lett.
406:83-88[Medline].
|
| 18.
|
Nociari, M. M.,
A. Shalev,
P. Benias, and C. Russo.
1998.
A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity.
J. Immunol. Methods
213:157-167[CrossRef][Medline].
|
| 19.
|
Ohmori, H.,
H. Ikeda,
T. Tanigawa, and M. Hikida.
1993.
Enzyme release assay of human NK cell activity using beta-galactosidase-expressing K562 target cell line.
J. Immunol. Methods
164:131-135[Medline].
|
| 20.
|
Ortaldo, J. R.,
G. D. Bonnard, and R. B. Herbermann.
1977.
Cytotoxic reactivity of human lymphocytes cultured in vitro.
J. Immunol.
119:1351-1357[Abstract/Free Full Text].
|
| 21.
|
Papadopoulos, N. G.,
G. V. Z. Dedoussis,
G. Spanakos,
A. D. Gritzapis,
C. N. Baxevanis, and M. Papamichail.
1994.
An improved fluorescence assay for the determination of lymphocyte-mediated cytotoxicity using flow cytometry.
J. Immunol. Methods
177:101-111[CrossRef][Medline].
|
| 22.
|
Roden, M. M.,
K.-H Lee,
M. C. Panelli, and F. M. Marincola.
1999.
A novel cytolysis assay using fluorescent labelling and quantitative fluorescent scanning technology.
J. Immunol. Methods
226:29-41[CrossRef][Medline].
|
| 23.
|
Suzuki, Y.,
K. Yoshikawa, and T. Yokochi.
1991.
A new sensitive and rapid automated fluorometric assay for detection of natural killer activity using carboxyfluorescein diacetate.
J. Immunoassay
12:145-157[Medline].
|
| 24.
|
Szekeres, J.,
A. S. Pacsa, and B. Pejtsik.
1981.
Measurement of lymphocyte cytotoxicity by assessing endogenous alkaline phosphatase activity of the target cells.
J. Immunol. Methods
40:151-154[Medline].
|
| 25.
|
Virag, L.,
C. Kerekgyarto, and J. Fachet.
1995.
A simple, rapid and sensitive fluorimetric assay for the measurement of cell-mediated cytotoxicity.
J. Immunol. Methods
185:199-208[CrossRef][Medline].
|
| 26.
|
Von Zons, P.,
P. Crowley-Nowick,
D. Friberg,
M. Bell,
U. Koldovsky, and T. L. Whiteside.
1997.
Comparison of europium and chromium release assays: cytotoxicity in healthy individuals and patients with cervical carcinoma.
Clin. Diagn. Lab. Immunol.
4:202-207[Abstract].
|
| 27.
|
Wang, X. M.,
P. I. Terasaki,
G. W. Rankin, Jr.,
D. Chia,
H. P. Zhong, and S. Hardy.
1993.
A new microcellular cytotoxicity test based on calcein AM release.
Hum. Immunol.
37:264-270[CrossRef][Medline].
|
| 28.
|
Wierda, W. G.,
D. S. Mehr, and Y. B. Kim.
1989.
Comparison of fluorochrome-labeled and 51Cr-labeled targets for natural killer cytotoxicity assay.
J. Immunol. Methods
122:15-24[CrossRef][Medline].
|
Clinical and Diagnostic Laboratory Immunology, November 2001, p. 1131-1135, Vol. 8, No. 6
1071-412X/01/$04.00+0 DOI: 10.1128/CDLI.8.6.1131-1135.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Tai, Y.-T., Li, X.-F., Catley, L., Coffey, R., Breitkreutz, I., Bae, J., Song, W., Podar, K., Hideshima, T., Chauhan, D., Schlossman, R., Richardson, P., Treon, S. P., Grewal, I. S., Munshi, N. C., Anderson, K. C.
(2005). Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40-Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications. Cancer Res.
65: 11712-11720
[Abstract]
[Full Text]
-
Bok, J. W., Balajee, S. A., Marr, K. A., Andes, D., Nielsen, K. F., Frisvad, J. C., Keller, N. P.
(2005). LaeA, a Regulator of Morphogenetic Fungal Virulence Factors. Eukaryot Cell
4: 1574-1582
[Abstract]
[Full Text]
-
Tai, Y.-T., Li, X., Tong, X., Santos, D., Otsuki, T., Catley, L., Tournilhac, O., Podar, K., Hideshima, T., Schlossman, R., Richardson, P., Munshi, N. C., Luqman, M., Anderson, K. C.
(2005). Human Anti-CD40 Antagonist Antibody Triggers Significant Antitumor Activity against Human Multiple Myeloma. Cancer Res.
65: 5898-5906
[Abstract]
[Full Text]
-
Yun, P. L. W., Decarlo, A. A., Chapple, C. C., Hunter, N.
(2005). Functional Implication of the Hydrolysis of Platelet Endothelial Cell Adhesion Molecule 1 (CD31) by Gingipains of Porphyromonas gingivalis for the Pathology of Periodontal Disease. Infect. Immun.
73: 1386-1398
[Abstract]
[Full Text]
-
Mueller, H., Kassack, M. U., Wiese, M.
(2004). Comparison of the Usefulness of the MTT, ATP, and Calcein Assays to Predict the Potency of Cytotoxic Agents in Various Human Cancer Cell Lines. J Biomol Screen
9: 506-515
[Abstract]